Essex Woodlands Management, Inc. Long-Term Concentrated

CIK: 0001542339 · Show all filings

Period: Q4 2018 (← Previous) (Next →)

Filing Date: Feb 14, 2019

Total Value ($000): $247,723 (100.0% shares, 0.0% debt)

Holdings (7)

— REVANCE THERAPEUTICS INC 37.0%

Value ($000) $91,739 Shares 3,342,047 Est. Cost $31.50 Unrealized —

— EYEPOINT 32.0%

Value ($000) $79,198 Shares 41,903,956 Est. Cost $2.49 Unrealized —

AXGN AXOGEN INC 22.6%

Value ($000) $55,973 Shares 2,739,751 Est. Cost $4.01 Unrealized +680.8%

MNOV MEDICINOVA INC 5.9%

Value ($000) $14,618 Shares 1,170,370 Est. Cost $2.95 Unrealized +238.2%

— ENDOLOGIX INC 2.2%

Value ($000) $5,355 Shares 1,257,468 Est. Cost $18.00 Unrealized —

— CATALYST 0.3%

Value ($000) $625 Shares 78,622 Est. Cost $4.80 Unrealized —

ACUR ACURA PHARMACEUTICALS INC 0.1%

Value ($000) $215 Shares 1,956,397 Est. Cost $3.40 Unrealized -94.1%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	REVANCE THERAPEUTICS INC	3,342,047	$91,739	37.0%	$31.50	—	COM	761330109
—	EYEPOINT	41,903,956	$79,198	32.0%	$2.49	—	COM	74440J101
AXGN	AXOGEN INC	2,739,751	$55,973	22.6%	$4.01	+680.8%	COM	05463X106
MNOV	MEDICINOVA INC	1,170,370	$14,618	5.9%	$2.95	+238.2%	COM	58468P206
—	ENDOLOGIX INC	1,257,468	$5,355	2.2%	$18.00	—	COM	29266S106
—	CATALYST	78,622	$625	0.3%	$4.80	—	COM	14888D109
ACUR	ACURA PHARMACEUTICALS INC	1,956,397	$215	0.1%	$3.40	-94.1%	COM	00509L802